Regeneron, Pfizer Tout Potential BCMA Bispecific Advantages At ASCO

Follow-Up May Explain Lower Cytopenias, KOL Says

 
• By Alaric DeArment
  
Regeneron
• Source: Shutterstock: lev radin
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from ASCO

More from Conferences